Highlights Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
7.88 ^USD	+0.77%		-5.17%	-31.12%

Mar. 28	Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	CI
Feb. 29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28	CI
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29	RE
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	Feb. 15	MT
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 15	CI
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $435M - $455M	Feb. 15	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q4 Revenue $117.6M	Feb. 15	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q4 EPS $-0.00	Feb. 15	MT
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
Ironwood Pharmaceuticals 2024 Revenue Outlook Trails Consensus; 2023 Guidance Maintained	Jan. 08	MT
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024	Jan. 08	CI
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2023 Revenue Range $435M - $450M	Nov. 09	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q3 Revenue $113.7M	Nov. 09	MT
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q3 EPS $0.12	Nov. 09	MT
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023	Nov. 09	CI
Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting	23-10-23	CI
Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity	23-10-16	CI
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old	23-10-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Highlights

Filters